Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Smith & Nephew Snats ( (SNN) ) has shared an update.
On November 7, 2025, Smith & Nephew plc announced the purchase of ordinary shares through its Dividend Re-Investment Plan following the interim dividend payment. This transaction, disclosed under the UK Market Abuse Regulation, involved key executives, including the CEO and presidents of various divisions, purchasing shares at a price of £12.4048 each. This move reflects the company’s commitment to aligning managerial interests with shareholder value, potentially impacting its market position positively.
The most recent analyst rating on (SNN) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company specializing in advanced wound management, orthopaedics, and sports medicine. The company focuses on providing innovative solutions to improve patient outcomes and is listed on the London Stock Exchange.
Average Trading Volume: 662,755
Technical Sentiment Signal: Buy
Current Market Cap: $14.12B
For detailed information about SNN stock, go to TipRanks’ Stock Analysis page.